MSD and Pfizer agree to license the production of drugs to treat Covid-19 to Vietnam


The Drug Administration of Vietnam (Ministry of Health) has just sent an official letter to the Vietnam Pharmaceutical Enterprises Association about the voluntary franchise to produce therapeutic drugs. Covid-19. Accordingly, the Drug Administration of Vietnam requests the Vietnam Pharmaceutical Business Association to soon notify the member drug manufacturers who wish to contact MSD or MPP Pharmaceutical Group to submit documents to become a partner. Voluntary franchise to manufacture the drug Molnupiravir.

Molnupiravir is used for home treatment of Covid-19 patients

Previously, on November 1, MSD Pharmaceutical Group announced that it had signed an agreement with the Drug Patent Pool (MPP). Accordingly, manufacturing facilities that want to obtain a voluntary franchise to produce Molnupiravir will submit an application to the MPP.

Along with that, the Drug Administration of Vietnam also sent an official dispatch to the Association, requesting the Association to inform member drug manufacturers that urgently need to contact Pfizer or MPP to submit an application to become a member. Franchise partner voluntarily produces the Covid-19 treatment Paxlovid (contains a combination of PF-07321332 and Ritonavir).

On November 20, the Drug Administration of Vietnam sent an official letter to Pfizer, asking the company to support Vietnamese pharmaceutical manufacturers in becoming Pfizer’s voluntary franchise partners to produce drugs. contains a combination of PF-07321332 and Ritonavir at the time of application. In response, Pfizer Company informed that MPP provided information for the manufacturer to contact and register directly with MPP to become a voluntary franchise partner of Pfizer to manufacture drugs containing PF combinations. -07321332 and Ritonavir. The application deadline is December 6.

MSD and Pfizer agree to license the production of Covid-19 treatment drugs for Vietnam - Photo 2.

Mild Covid-19 patients are monitored and treated at home – Illustration

The Drug Administration of Vietnam requests the Association to inform member drug manufacturers that urgently need access to information to register to become a voluntary franchising partner for the production of drugs containing the combination of PF 07321332 and Ritonavir. This is a new antiviral drug that works to support the treatment of Covid-19.

Recently, 5 domestic pharmaceutical companies submitted dossiers to produce antiviral drugs to treat Covid-19. The Ministry of Health is considering submitting to the Government for approval for licensing in the case of an emergency epidemic prevention and control situation, with a number of terms on the application being shortened. If approved, it is expected that 5 registration numbers will be issued for 5 Molnupiravir drugs manufactured by domestic pharmaceutical companies.

In Vietnam, in August 2021, the drug Molnupiravir was piloted by the Ministry of Health to treat F0 with mild symptoms at home in Ho Chi Minh City. After the effectiveness of this drug, so far, 34 provinces and cities have managed to provide controlled treatment with the antiviral drug Molnupiravir for mild and asymptomatic COVID-19 patients at home.

The results recently announced by the Ministry of Health show that the drug has high safety, good tolerability, obvious effectiveness in reducing viral load, reducing spread, reducing severe transfer, shortening treatment time after 5 the day the patient tested positive. In addition, the rate of severe transfer was very low from 0.02% to 0.06% and there were no deaths.

MSD and Pfizer agree to license the production of Covid-19 treatment drugs for Vietnam - Photo 3.



Leave a Reply

Your email address will not be published. Required fields are marked *